Tag Archives: bio

BIO IP & Diagnostics Conference – Is the Titanic Turning Around?

Posted on September 21, 2018 by Warren Woessner

On September 28th, I will be moderating a panel on patenting diagnostic tests – and related subject matter – such as methods of medical treatment, at BIO’s annual IP & Diagnostics Symposium in Alexandria, VA. At the beginning of 2018, … Continue reading →

Posted in BIO, Patent Eligible Subject Matter | Tagged Berkheimer, bio, IP & Diagnostics Symposium, Mayo/Alice, PTAB, Warren Woessner | Leave a comment

BIO Provides Supplemental Comments on PTO s.101 Guidelines

Posted on October 21, 2014 by Warren Woessner

BIO recently generated a letter to the PTO on the March 6th Guidelines on the patent-eligibility of subject matter in the life sciences, particularly “natural products.” BIO invited a group of in-house and private practitioners to comment on the Guidelines … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged bio, biotechnology, biotechnology law, Patent Law, patents, USPTO, Warren Woessner | Leave a comment

FDA Publishes “Purple Book” for Biologicals/Biosimilars

Posted on September 11, 2014 by Warren Woessner

In a major move to get organized for the oncoming wave of biosimilar applications, the FDA has published a “Purple Book” listing licensed (e.g., approved) biologicals and licensed interchangeable biosimilars. Rather than summarize the contents table of the book, linked … Continue reading →

Posted in 2017 Patent Review | Tagged bio, FDA, intellectual property, Purple Book, Warren Woessner | Leave a comment

101 Rejections Under the Guidelines: Mayo and Myriad “Go Viral”

Posted on September 4, 2014 by Warren Woessner

This is a guest post from Hans Sauer, Deputy General Counsel, Intellectual Property for BIO. “Recently, I set out to find real-world examples of recent rejections under the USPTO Guidance, to do my own sampling rather than rely on reported … Continue reading →